{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:16:32Z","timestamp":1790198192194,"version":"4.1.0"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"publisher","award":["12567"],"award-info":[{"award-number":["12567"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Dutch Research Council","doi-asserted-by":"publisher","award":["09150172010054"],"award-info":[{"award-number":["09150172010054"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.nucmedbio.2024.108971","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T14:12:05Z","timestamp":1731507125000},"page":"108971","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["The potential of targeted radionuclide therapy to treat hypoxic tumor cells"],"prefix":"10.1016","volume":"140-141","author":[{"given":"S.T.M.","family":"Wenker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.M.","family":"van Lith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tamborino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.W.","family":"Konijnenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bussink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Heskamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2024.108971_bb0005","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1053\/j.semnuclmed.2014.10.002","article-title":"Biology of hypoxia","volume":"45","author":"Span","year":"2015","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0010","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1259\/0007-1285-52-620-650","article-title":"Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation","volume":"52","author":"Brown","year":"1979","journal-title":"Br J Radiol"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0015","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/bjc.1955.55","article-title":"The histological structure of some human lung cancers and the possible implications for radiotherapy","volume":"9","author":"Thomlinson","year":"1955","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0020","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0360-3016(00)00686-6","article-title":"Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: a quantitative multi-parameter analysis","volume":"48","author":"Rijken","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0025","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2015.50","article-title":"Hypoxia and metabolic adaptation of cancer cells","volume":"5","author":"Eales","year":"2016","journal-title":"Oncogenesis"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0030","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41416-019-0642-z","article-title":"Carbonic anhydrase IX and acid transport in cancer","volume":"122","author":"Becker","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0035","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1158\/1078-0432.CCR-12-0858","article-title":"Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy","volume":"18","author":"Meijer","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0040","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","article-title":"Inhibitory effect of tumor cell-derived lactic acid on human T cells","volume":"109","author":"Fischer","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0045","first-page":"453","article-title":"Lactate enhances motility of tumor cells and inhibits monocyte migration and cytokine release","volume":"39","author":"Goetze","year":"2011","journal-title":"Int J Oncol"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0050","doi-asserted-by":"crossref","first-page":"6921","DOI":"10.1158\/0008-5472.CAN-11-1457","article-title":"Lactate: a metabolic key player in cancer","volume":"71","author":"Hirschhaeuser","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0055","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3390\/cancers11010112","article-title":"Hypoxic radioresistance: can ROS be the key to overcome it?","volume":"11","author":"Wang","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0060","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrc3064","article-title":"Targeting hypoxia in cancer therapy","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-60761-786-0_1","article-title":"Hypoxic tumours and their effect on immune cells and cancer therapy","volume":"651","author":"Yotnda","year":"2010","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0070","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/JCO.2007.12.7878","article-title":"Hypoxic radiosensitization: adored and ignored","volume":"25","author":"Overgaard","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0075","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S1470-2045(02)00929-4","article-title":"ARCON: a novel biology-based approach in radiotherapy","volume":"3","author":"Kaanders","year":"2002","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0080","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1053-4296(96)80033-6","article-title":"Hypoxia-specific cytotoxins in cancer therapy","volume":"6","author":"Brown","year":"1996","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0085","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.molonc.2008.03.006","article-title":"Molecular aspects of tumour hypoxia","volume":"2","author":"Rademakers","year":"2008","journal-title":"Mol Oncol"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0090","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1158\/1078-0432.CCR-20-3913","article-title":"Targeting oxidative phosphorylation to increase the efficacy of radio- and immune-combination therapy","volume":"27","author":"Boreel","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0095","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2022.14","article-title":"Exploring hypoxic biology to improve radiotherapy outcomes","volume":"24","author":"Li","year":"2022","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0100","series-title":"Radiobiology for the radiologist","author":"Hall","year":"2006"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0105","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/jnci\/93.4.266","article-title":"Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects","volume":"93","author":"H\u00f6ckel","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0110","first-page":"12","article-title":"Introduction to radiobiology of targeted radionuclide therapy","volume":"2","author":"Pouget","year":"2015","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0115","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1007\/s00259-021-05340-0","article-title":"To 1000 Gy and back again: a systematic review on dose-response evaluation in selective internal radiation therapy for primary and secondary liver cancer","volume":"48","author":"Roosen","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0120","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.3390\/molecules27175429","article-title":"Radionuclides for targeted therapy: physical properties","volume":"27","author":"Stokke","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0125","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.3390\/molecules25071743","article-title":"Targeted radionuclide therapy of prostate cancer-from basic research to clinical perspectives","volume":"25","author":"Czerwinska","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0130","first-page":"317","article-title":"The effect of oxygen on impairment of the proliferative capacity of human cells in culture by ionizing radiations of different LET","volume":"10","author":"Barendsen","year":"1966","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0135","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1667\/0033-7587(2000)154[0485:IOAAHC]2.0.CO;2","article-title":"Inactivation of aerobic and hypoxic cells from three different cell lines by accelerated 3He-,12C- and 20Ne-ion beams","volume":"154","author":"Furusawa","year":"2000","journal-title":"Radiat Res"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0140","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1088\/0031-9155\/56\/11\/006","article-title":"Modelling of the oxygen enhancement ratio for ion beam radiation therapy","volume":"56","author":"Wenzl","year":"2011","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0145","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/09553009314551421","article-title":"Induction and rejoining of DNA double-strand breaks in V79-4 mammalian cells following \u03b3- and \u03b1-irradiation","volume":"64","author":"Jenner","year":"1993","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0150","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3390\/pharmaceutics13060906","article-title":"Overview of the most promising radionuclides for targeted alpha therapy: the \u201chopeful eight\u201d","volume":"13","author":"Eychenne","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0155","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2967\/jnumed.116.186338","article-title":"\u03b1-Emitters for radiotherapy: from basic radiochemistry to clinical studies-part 1","volume":"59","author":"Poty","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0160","unstructured":"National Institute of Standards and Technology. eStar. https:\/\/physics.nist.gov\/PhysRefData\/Star\/Text\/ESTAR.html."},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0165","unstructured":"National Nuclear Data Center. NuDat 3.0. https:\/\/www.nndc.bnl.gov\/nudat3\/."},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0170","unstructured":"National Institute of Standards and Technology. aStar. https:\/\/physics.nist.gov\/PhysRefData\/Star\/Text\/ASTAR.html."},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0175","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41181-019-0075-2","article-title":"Auger electrons for cancer therapy \u2013 a review","volume":"4","author":"Ku","year":"2019","journal-title":"EJNMMI Radiopharmacy and Chemistry"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0180","unstructured":"IAEA. LiveChart of Nuclides. https:\/\/www-nds.iaea.org\/relnsd\/vcharthtml\/VChartHTML.html#dcy1."},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0185","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1118\/1.3615164","article-title":"3D modeling of effects of increased oxygenation and activity concentration in tumors treated with radionuclides and antiangiogenic drugs","volume":"38","author":"Lagerlof","year":"2011","journal-title":"Med Phys"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0190","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2967\/jnumed.108.058651","article-title":"MIRD pamphlet no. 22 (abridged): radiobiology and dosimetry of \u03b1-particle emitters for targeted radionuclide therapy","volume":"51","author":"Sgouros","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0195","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.nucmedbio.2020.01.003","article-title":"The effect of hypoxia on the induction of strand breaks in plasmid DNA by alpha-, beta- and Auger electron-emitters 223Ra, 188Re, 99mTc and DNA-binding 99mTc-labeled pyrene","volume":"80-81","author":"Reissig","year":"2020","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0200","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3413\/Nukmed-0950-17-12","article-title":"Radiotoxicity of alpha particles versus high and low energy electrons in hypoxic cancer cells","volume":"57","author":"Maucksch","year":"2018","journal-title":"Nuklearmedizin"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0205","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.apradiso.2019.01.021","article-title":"Effect of 177Lu-iPSMA on viability and DNA damage of human glioma cells subjected to hypoxia-mimetic conditions","volume":"146","author":"Azorin-Vega","year":"2019","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064730","article-title":"Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation","volume":"8","author":"Wulbrand","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0215","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.apradiso.2014.03.006","article-title":"Monte Carlo simulations of dose distributions with necrotic tumor targeted radioimmunotherapy","volume":"90","author":"Penfold","year":"2014","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0220","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1097\/MNM.0000000000000199","article-title":"Targeted \u03b1-therapy using 227Th-APOMAB and cross-fire antitumour effects: preliminary in-vivo evaluation","volume":"35","author":"Staudacher","year":"2014","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0225","doi-asserted-by":"crossref","first-page":"54795","DOI":"10.18632\/oncotarget.10758","article-title":"Hypoxia-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated sodium iodide symporter gene delivery","volume":"7","author":"M\u00fcller","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0230","article-title":"Imaging of tumor hypoxia with radionuclide-labeled tracers for PET","volume":"11","author":"Huang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0235","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1524\/ract.2006.94.6.375","article-title":"Preparation and preliminary biological evaluation of a 177Lu labeled nitroimidazole derivative for possible use in targeted tumor therapy","volume":"94","author":"Das","year":"2006","journal-title":"Radiochim Acta"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0240","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.nucmedbio.2005.04.019","article-title":"[131I]Iodoazomycin arabinoside for low-dose-rate isotope radiotherapy: radiolabeling, stability, long-term whole-body clearance and radiation dosimetry estimates in mice","volume":"32","author":"Kumar","year":"2005","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0245","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2174\/1874471011306020004","article-title":"[131I]IAZA as a molecular radiotherapeutic (MRT) drug: wash-out with cold IAZA accelerates clearance in a murine tumor model","volume":"6","author":"Mercer","year":"2013","journal-title":"Curr Radiopharm"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0250","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/cmdc.201600213","article-title":"Synthesis and biological evaluation of iodoglucoazomycin (I-GAZ), an azomycin-glucose adduct with putative applications in diagnostic imaging and radiotherapy of hypoxic tumors","volume":"11","author":"Kumar","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0255","first-page":"1155","article-title":"Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential","volume":"38","author":"Fujibayashi","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0260","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.nucmedbio.2004.08.012","article-title":"Basic characterization of 64Cu-ATSM as a radiotherapy agent","volume":"32","author":"Obata","year":"2005","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0265","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s00259-009-1305-8","article-title":"Radiobiological effects of hypoxia-dependent uptake of 64Cu-ATSM: enhanced DNA damage and cytotoxicity in hypoxic cells","volume":"37","author":"Weeks","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0270","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1073\/pnas.98.3.1206","article-title":"Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): an agent for radiotherapy","volume":"98","author":"Lewis","year":"2001","journal-title":"PNAS"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0275","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.canlet.2016.03.020","article-title":"64Cu-ATSM therapy targets regions with activated DNA repair and enrichment of CD133+ cells in an HT-29 tumor model: sensitization with a nucleic acid antimetabolite","volume":"376","author":"Yoshii","year":"2016","journal-title":"Cancer Lett"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0280","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.7150\/thno.20982","article-title":"Cancer radiotheranostics targeting carbonic anhydrase-IX with 111In- and 90Y-labeled ureidosulfonamide scaffold for SPECT imaging and radionuclide-based therapy","volume":"8","author":"Iikuni","year":"2018","journal-title":"Theranostics"},{"issue":"192\u2013200","key":"10.1016\/j.nucmedbio.2024.108971_bb0285","first-page":"9","article-title":"Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons","volume":"170","author":"Pouget","year":"2008","journal-title":"Radiat Res"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0290","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.2967\/jnumed.122.265039","article-title":"Marshalling the potential of auger electron radiopharmaceutical therapy","volume":"64","author":"Bolcaen","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0295","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40658-023-00589-w","article-title":"Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection","volume":"10","author":"Verburg","year":"2023","journal-title":"EJNMMI Phys"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0300","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40658-020-00301-2","article-title":"Radiation doses from 161Tb and 177Lu in single tumour cells and micrometastases","volume":"7","author":"Alcocer-\u00c1vila","year":"2020","journal-title":"EJNMMI Phys"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0305","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/jat.3749","article-title":"The use of cobalt chloride as a chemical hypoxia model","volume":"39","author":"Munoz-Sanchez","year":"2019","journal-title":"J Appl Toxicol"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0310","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1152\/physiolgenomics.00045.2004","article-title":"Gene expression profiling of hypoxia signaling in human hepatocellular carcinoma cells","volume":"22","author":"Vengellur","year":"2005","journal-title":"Physiol Genomics"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0315","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/1471-2407-11-167","article-title":"Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1\u03b1, CAIX, LDH-5, GLUT-1, MCT1 and MCT4","volume":"11","author":"Rademakers","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0320","series-title":"Dosimetry for radiopharmaceutical therapy","author":"IAEA","year":"2024"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0325","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3390\/pharmaceutics13010049","article-title":"Targeted alpha therapy: Progress in radionuclide production, radiochemistry, and applications","volume":"13","author":"Nelson","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0330","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1088\/0031-9155\/56\/3\/012","article-title":"Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody","volume":"56","author":"Schwartz","year":"2011","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0335","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23030581","article-title":"Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators","volume":"23","author":"Kozempel","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(17)30379-0","article-title":"Targeted radionuclide therapy in combined-modality regimens","volume":"18","author":"Gill","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0345","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-13-0143","article-title":"CTLA-4 and PD-1\/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients","volume":"19","author":"Ott","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0350","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.7150\/thno.96944","article-title":"Towards effective CAIX-targeted radionuclide and checkpoint inhibition combination therapy for advanced clear cell renal cell carcinoma","volume":"14","author":"Kleinendorst","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0355","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1073\/pnas.1621363114","article-title":"cGAS is essential for the antitumor effect of immune checkpoint blockade","volume":"114","author":"Wang","year":"2017","journal-title":"PNAS"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0360","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1158\/1078-0432.CCR-21-4332","article-title":"Combining targeted radionuclide therapy and immune checkpoint inhibition for cancer treatment","volume":"28","author":"Kleinendorst","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0365","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/cancers16010191","article-title":"Comparative study of the effect of radiation delivered by Lutetium-177 or Actinium-225 on anti-GD2 chimeric antigen receptor T cell viability and functions","volume":"16","author":"Sodji","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0370","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201903628","article-title":"Hybrid protein nano-reactors enable simultaneous increments of tumor oxygenation and iodine-131 delivery for enhanced radionuclide therapy","volume":"15","author":"Chen","year":"2019","journal-title":"Small"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0375","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.1039\/C7NR08747K","article-title":"Nano-graphene oxide-manganese dioxide nanocomposites for overcoming tumor hypoxia and enhancing cancer radioisotope therapy","volume":"10","author":"Tao","year":"2018","journal-title":"Nanoscale"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0380","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201700640","article-title":"Albumin-templated manganese dioxide nanoparticles for enhanced radioisotope therapy","volume":"13","author":"Tian","year":"2017","journal-title":"Small"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0385","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.ymthe.2018.02.019","article-title":"Radionuclide imaging-guided chemo-radioisotope synergistic therapy using a 131I-labeled polydopamine multifunctional nanocarrier","volume":"26","author":"Li","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0390","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7150\/thno.17381","article-title":"Radionuclide I-131 labeled albumin-paclitaxel nanoparticles for synergistic combined chemo-radioisotope therapy of cancer","volume":"7","author":"Tian","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0395","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1002\/smll.201601375","article-title":"Rhenium-188 labeled tungsten disulfide nanoflakes for self-sensitized, near-infrared enhanced radioisotope therapy","volume":"12","author":"Chao","year":"2016","journal-title":"Small"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0400","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1470-2045(09)70353-5","article-title":"PET-CT for response assessment and treatment adaptation in head and neck cancer","volume":"11","author":"Bussink","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0405","doi-asserted-by":"crossref","first-page":"14620","DOI":"10.1073\/pnas.1102526108","article-title":"Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging","volume":"108","author":"Dubois","year":"2011","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0410","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/bjc.1992.17","article-title":"Non-invasive assessment of human tumor hypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study","volume":"65","author":"Parliament","year":"1991","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nucmedbio.2024.108971_bb0415","doi-asserted-by":"crossref","first-page":"18898","DOI":"10.1038\/s41598-019-54824-5","article-title":"CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models","volume":"9","author":"Huizing","year":"2019","journal-title":"Sci Rep"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805124000970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805124000970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T16:32:08Z","timestamp":1741710728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805124000970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":83,"alternative-id":["S0969805124000970"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108971","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The potential of targeted radionuclide therapy to treat hypoxic tumor cells","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108971","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108971"}}